The firm is a medical technology company based on the East Coast. The firm works with early-stage startups using a variety of structures including co-development, equity investments, licensing, and acquisitions (most common). In terms of equity investments, the $850M USD firm invests in companies from Series A to Series C (or later) with an average of $3-5M as the initial size of investment. In terms of acquisitions, the firm has done deals in the range of $10s to $100s of millions of dollars. The firm is interested in partnerships with breakthrough, disruptive technologies. The firm is a multi-stage investor and is interested in technologies worldwide.
The firm is interested in disruptive technologies that are strategically related to the company’s focus on digestive health and pain management. The firm is primarily interested in medical devices and digital health. Within medical devices, the firm is primary interested in 510K and De Novo’s and are open to PMA devices. The firm will consider working with companies at any stage of development. Within digital health, the firm is most interested in consumer facing products that are linked back to medical devices, and the associated data analytics around the products.
The firm primarily values a management team with technical experience as they are interested in promising disruptive technology. The firm also prefers a team with previous management experience. The firm acts as a strategic investor in equity investments. As a strategic investor, the firm will require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment